Jove
Visualize
Contact Us

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

374
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
374
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

144
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
144
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

315
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
315
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

55
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
55
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

498
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
498
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

42
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
42
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Qx-314 Inhibits Acid-induced Esophageal Hypersensitivity By Regulating Trpv1/nav1.8 Receptor Pathway.
  1. Home
  3. Qx-314 Inhibits Acid-induced Esophageal Hypersensitivity By Regulating Trpv1/nav1.8 Receptor Pathway.

Related Experiment Video

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.0K

QX-314 inhibits acid-induced esophageal hypersensitivity by regulating TRPV1/NaV1.8 receptor pathway.

Baixin Wu1, Yuzhen Ciren1, Shuai Peng1

  • 1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Digestive Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China.

International Immunopharmacology
|May 7, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

QX-314 selectively inhibits acid-induced esophageal hypersensitivity in GERD by blocking TRPV1 and NaV1.8 channels in the jugular ganglion, reducing sensory conduction and inflammation.

More Related Videos

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

8.1K
In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments
10:32

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments

Published on: October 25, 2016

11.4K

Related Experiment Videos

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.0K
Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

8.1K
In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments
10:32

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments

Published on: October 25, 2016

11.4K

Area of Science:

  • Gastroenterology
  • Neuroscience
  • Pharmacology

Background:

  • Gastroesophageal reflux disease (GERD) causes discomfort linked to esophageal hypersensitivity.
  • Transient Receptor Potential Vanilloid 1 (TRPV1) channels are implicated in acid-induced esophageal hypersensitivity.
  • QX-314 is a compound known to block TRPV1 channels.

Purpose of the Study:

  • To investigate QX-314's role in inhibiting esophageal sensory conduction in a GERD guinea pig model.
  • To evaluate QX-314's effect on inflammation and specific ion channel expression in GERD.

Main Methods:

  • Constructed an acid-induced GERD guinea pig model.
  • Assessed esophageal inflammation markers and scores.
  • Examined TRPV1 and NaV1.8 co-localization via immunofluorescence.
  • Quantified TRPV1 and NaV1.8 expression using Western Blot and RT-qPCR.

    • Main Results:

    • GERD model showed inflammatory infiltration and elevated IL-1β, IL-6, TNF-α, with decreased IL-10 after QX-314 treatment.
    • TRPV1 and NaV1.8 expression and co-localization were upregulated in the esophagus and jugular ganglion of GERD group.
    • QX-314 suppressed TRPV1 and NaV1.8 expression in the esophagus and jugular ganglion, with no effect on the nodose ganglion.

    Conclusions:

    • QX-314 inhibits esophageal sensory conduction by blocking NaV1.8 channels via TRPV1 in the jugular ganglion.
    • QX-314 reduces acid-induced esophageal hypersensitivity and inflammation in GERD.
    • QX-314 demonstrates selective efficacy for esophageal hypersensitivity in the context of acid exposure.